Marshall Wace LLP Takes $212,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Marshall Wace LLP acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 4,426 shares of the biopharmaceutical company's stock, valued at approximately $212,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $60,054,000. Arrowstreet Capital Limited Partnership increased its holdings in shares of Halozyme Therapeutics by 141.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock valued at $47,470,000 after acquiring an additional 581,475 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $21,838,000. Vanguard Group Inc. increased its holdings in shares of Halozyme Therapeutics by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after acquiring an additional 386,618 shares during the period. Finally, Janney Montgomery Scott LLC increased its holdings in shares of Halozyme Therapeutics by 698.8% in the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company's stock valued at $13,756,000 after acquiring an additional 251,711 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the sale, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. The trade was a 5.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the sale, the director now owns 33,611 shares in the company, valued at $1,972,629.59. The trade was a 12.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 21,697 shares of company stock worth $1,276,552. Corporate insiders own 2.90% of the company's stock.

Halozyme Therapeutics Stock Performance

HALO traded down $1.87 during trading on Friday, hitting $65.86. The stock had a trading volume of 2,501,725 shares, compared to its average volume of 1,499,455. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The firm has a market capitalization of $8.14 billion, a P/E ratio of 19.20, a PEG ratio of 0.42 and a beta of 1.26. The company's 50-day moving average price is $61.45 and its 200 day moving average price is $55.88. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping the consensus estimate of $0.98 by $0.13. The company had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business's revenue was up 35.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.79 EPS. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Benchmark cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday. HC Wainwright reaffirmed a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a report on Friday, April 25th. Finally, Wells Fargo & Company lifted their target price on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a report on Wednesday. Five analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $63.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.